Ocular hypotensive effect of ONO-9054, an EP3/FP receptor agonist: Results of a randomized, placebo-controlled, dose escalation study

Journal of Glaucoma

Volumn 25, Issue 10, 2016, Pages e826-e833

  Harris, Alon ^a   Ward, Caroline L ^b   Rowe Rendleman, Cheryl L ^c   Ouchi, Takafumi ^b   Wood, Andrew ^b   Fujii, Akifumi ^b   Serle, Janet B ^d  

^a INDIANA UNIVERSITY   (United States)

^b ONO PHARMACEUTICAL CO   (Japan)

^c Omar Consulting Group LLC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ocular hypertension; ONO 9054; open angle glaucoma; sepetaprost

Indexed keywords

ANTIHYPERTENSIVE AGENT; ONO 9054; PLACEBO; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; OXEPINE DERIVATIVE; PROPAN-2-YL 4-(6-(4-(2,5-DIFLUOROPHENOXY)-3-HYDROXYBUT-1-EN-1-YL)-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOATE; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; EYE EXAMINATION; FEMALE; HEADACHE; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UVEITIS; VITREOUS BODY DETACHMENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY;

AGED; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OXEPINS; RECEPTORS, PROSTAGLANDIN; TONOMETRY, OCULAR;

EID: 84974688543     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0000000000000449     Document Type: Article

References (22)

1. Friedman DS, Wolfs RC, O'Colmain BJ,. Prevalence of open angle glaucoma among adults in the United States. Arch Ophthalmol. 2004; 122: 532-538.
2. Jacobs DS,. Open-Angle glaucoma: epidemiology, clinical presentation, and diagnosis. Available at: www.uptodate.com/contents/open-Angle-glaucoma-epidemiology-clinical-presentation-And-diagnosis. Accessed June 22, 2015.
3. Martínez-Belló C, Chauhan BC, Nicolela MT,. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol. 2000; 129: 302-308.
4. Turner SA, McNaught AI,. First-line treatment in open-Angle glaucoma: an update. Expert Rev Ophthalmol. 2013; 8: 587-594.
5. Burr J, Azuara-Blanco A, Avenell A,. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012; 9: CD004399.
6. Lin L, Zhao YJ, Chew PT,. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-Angle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48: 1585-1593.
7. Covert D, Robin AL,. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006; 22: 971-976.
8. Sharif NA, Kelly CR, Crider JY,. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003; 19: 501-515.
9. 3 and FP receptors-in monkeys. Invest Ophthalmol Vis Sci. 2015; 56: 2547-2552.
10. Karakawa T, Yamane S, Goto Y,. Invest Ophthalmol Vis Sci. 2015;56(7). Abstract 1974, poster presented at ARVO 2015.
11. Suto F, Rowe-Rendleman CL, Ouchi T,. A novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers. Invest Ophthalmol Vis Sci. 2015; 56: 7963-7970.
12. Doi LM, Melo LA Jr, Prata JA Jr,. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial. Br J Ophthalmol. 2005; 89: 547-549.
13. Raber S, Courtney R, Maeda-Chubachi T,. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study. Ophthalmology. 2011; 118: 2022-2027.
14. Hedman K, Alm A,. A pooled-data analysis of three randomised, double-masked six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000; 10: 95-104.
15. Xalatan latanoprost ophthalmic solution, 0.005% (50 μg/mL) prescribing information/Package Insert, Pfizer, New York, NY, 2011. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=613. Accessed June 22, 2015.
16. Hopkins GA, Lyle WM,. Potential systemic effects of six common ophthalmic drugs. J Am Optometric Assoc. 1977; 48: 1241-1245.
17. Gray C,. Systemic toxicity with topical ophthalmic medications in children. Paed Peri Drug Ther. 2006; 7: 23-29.
18. Korte JM, Kaila T, Saari KM,. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eye drops. Graefes Arch Clin Exp Ophthalmol. 2002; 240: 430-435.
19. Salminen L,. Review: systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol. 1990; 6: 243-249.
20. Eyawo O, Nachega J, Lefebvre P,. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-Angle glaucoma or ocular hypertension: a meta-Analysis. Clin Ophthal. 2009; 3: 447-456.
21. Kucukevcilioglu M, Bayer A, Uysal Y,. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Experiment Ophthalmol. 2014; 42: 126-131.
22. Herndon LW, Williwams RD, Wand M,. Increased periocular pigmentation with ocular hypotensive use in African Americans. Am J Ophthalmol. 2003; 135: 713-715.